Advertisement

 

 

HIV-1 genetic diversity and primary drug resistance mutations before large-scale access to antiretroviral therapy, Republic of Congo.

HIV-1 genetic diversity and primary drug resistance mutations before large-scale access to antiretroviral therapy, Republic of Congo.
Author Information (click to view)

Niama FR, Vidal N, Diop-Ndiaye H, Nguimbi E, Ahombo G, Diakabana P, Bayonne Kombo ÉS, Mayengue PI, Kobawila SC, Parra HJ, Toure-Kane C,


Niama FR, Vidal N, Diop-Ndiaye H, Nguimbi E, Ahombo G, Diakabana P, Bayonne Kombo ÉS, Mayengue PI, Kobawila SC, Parra HJ, Toure-Kane C, (click to view)

Niama FR, Vidal N, Diop-Ndiaye H, Nguimbi E, Ahombo G, Diakabana P, Bayonne Kombo ÉS, Mayengue PI, Kobawila SC, Parra HJ, Toure-Kane C,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

BMC research notes 2017 07 0510(1) 243 doi 10.1186/s13104-017-2550-8

Abstract
BACKGROUND
In this work, we investigated the genetic diversity of HIV-1 and the presence of mutations conferring antiretroviral drug resistance in 50 drug-naïve infected persons in the Republic of Congo (RoC). Samples were obtained before large-scale access to HAART in 2002 and 2004.

METHODS
To assess the HIV-1 genetic recombination, the sequencing of the pol gene encoding a protease and partial reverse transcriptase was performed and analyzed with updated references, including newly characterized CRFs. The assessment of drug resistance was conducted according to the WHO protocol.

RESULTS
Among the 50 samples analyzed for the pol gene, 50% were classified as intersubtype recombinants, charring complex structures inside the pol fragment. Five samples could not be classified (noted U). The most prevalent subtypes were G with 10 isolates and D with 11 isolates. One isolate of A, J, H, CRF05, CRF18 and CRF37 were also found. Two samples (4%) harboring the mutations M230L and Y181C associated with the TAMs M41L and T215Y, respectively, were found.

CONCLUSION
This first study in the RoC, based on WHO classification, shows that the threshold of transmitted drug resistance before large-scale access to antiretroviral therapy is 4%.

Submit a Comment

Your email address will not be published. Required fields are marked *

1 × two =

[ HIDE/SHOW ]